about
The Utility of Molecular Imaging in Prostate CancerProstate-specific membrane antigen as a target for cancer imaging and therapyIn vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imagingA 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Cancer stratification by molecular imaging.Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerPSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancerAlterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyDevelopment of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Molecular and functional imaging for detection of lymph node metastases in prostate cancer.Molecular imaging agents for SPECT (and SPECT/CT).Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Continued rapid growth in (68) Ga applications: update 2013 to June 2014.Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRIComparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?Meeting the challenges of PET-based molecular imaging in cancer.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection.PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.Lymph node imaging in initial staging of prostate cancer: An overview and update.Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [68Ga]-Labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron Emission Tomography) Tracer.[Significance of PSMA imaging in prostate cancer].(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.Writing PET into existence.
P2860
Q26764746-BC5E5651-E0EC-4A94-A7D2-F137F29C6F52Q26799439-77A21531-6E41-40E9-91B3-2BD58FF7D1B6Q28535729-F05FF359-31A7-4D92-983A-9DF2FC7761B3Q30491961-31EE860A-34CD-42EA-B71E-572984E7F8FFQ35043569-CA690A74-4FC8-4079-926C-4B951FD2E017Q35380664-76073AAC-6A3C-4B0F-8CAD-F906785FE7C5Q35938051-0D72DE17-18EE-45A6-8886-BCB2D9DA76D8Q36109230-160E799A-4D5B-43FC-BE15-C73EDEBEEAA6Q36289592-01912A46-4116-4975-9ED2-BA504CFAF624Q36363280-8BBC109D-9D7B-4F6C-8035-A851AAA2B29CQ37350456-CC2AD4DB-40FA-4E42-A6F7-913D03F057A6Q37390674-5D0D250B-050E-41F8-8E2A-F0D9615D5510Q38119113-6B13F64A-60DA-49CF-9B4D-8559D51CBFFAQ38169570-CA29B010-9476-44F8-92D3-89EBAD88F374Q38321182-611C2568-BC6A-4088-9A19-82FE87D05DA5Q38358666-8E016B4A-EA58-4C6B-A9C6-8A3AF76362CEQ38564109-43B62065-E108-4F34-9374-AE969CB524E2Q38619857-191C2869-2270-44AE-892B-50A6522C6A80Q38639486-04DF3FFB-4838-4375-8991-7A1C3BF9E0EBQ38773634-AC5C6B2A-51D0-49B5-87AD-2915F5FA29D2Q39017235-8DD90C98-C52C-4F4C-86D2-1118F05A4856Q39276928-761FC553-E3E1-48A1-A3D1-4678DC8799FCQ39345390-733DF55F-8556-4D92-90FF-DDB2F623D5F0Q39828822-B747262A-2073-4BBB-AE86-81CC66558C9DQ39869574-31BAE05E-44F5-409A-81F3-DF69F73146FAQ40434230-26C77B85-5434-4063-AF48-B5589F75EED1Q41273648-F031EA6F-9E75-42A2-83FC-DFEB0FDF8726Q43119026-2B846894-F0DD-41E8-BE0A-EE0A9052EDD8Q45871873-6E60FB57-AA2D-4468-8006-0F1D1F793C74Q47105948-98FF86A6-9690-415A-9936-9A74016144B8Q47147617-991BB74D-B733-4579-900C-0F7D82F5329DQ47157403-EEA87E40-17F9-4656-9D6B-EE89BBABE0C1Q47588415-7538C5B2-044B-4E02-9DF9-F02DEA22F46FQ47693515-7B7BFDA8-7C82-48AC-B1D6-97DA6BB96497Q48905216-CD717D2D-3C6E-4642-B059-FDE79E70D126Q52665542-92582DE2-BA68-42A8-9813-392EC4E58ECDQ52937814-CA564EAE-DB5B-4CFD-B025-F5F72AA30F5FQ52985772-2F2DFEEC-CAF3-4C6C-A9A9-80EA9A504809Q53070213-C8CD027C-0BAA-4A75-86AB-7CF86FBA98C6Q53094162-D6CB51EA-883D-4459-8D4E-F856175B0389
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
PSMA as a target for radiolabelled small molecules.
@en
PSMA as a target for radiolabelled small molecules.
@nl
type
label
PSMA as a target for radiolabelled small molecules.
@en
PSMA as a target for radiolabelled small molecules.
@nl
prefLabel
PSMA as a target for radiolabelled small molecules.
@en
PSMA as a target for radiolabelled small molecules.
@nl
P2093
P2860
P1476
PSMA as a target for radiolabelled small molecules.
@en
P2093
John Babich
Matthias Eder
Michael Eisenhut
Uwe Haberkorn
P2860
P2888
P304
P356
10.1007/S00259-013-2374-2
P577
2013-06-01T00:00:00Z